Q-omics provides the consensus-scored TTC9C profile across patient tissues and cancer cell-line models. TTC9C expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TTC9C is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, TTC9C RNA expression shows 19,072 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, BLCA, and ACC as cancer lineages where TTC9C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC9C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC9C survival associations across molecular data types. TTC9C RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC9C RNA expression–survival associations across cancer types. High TTC9C expression shows unfavorable associations in KIRP, ACC, LIHC, PAAD, KICH and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TTC9C RNA expression.
This table summarizes TTC9C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC9C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC9C shows higher tumor expression in BLCA, KIRC, HNSC, LIHC, LUAD and COAD. The BLCA box plot shows higher TTC9C RNA expression in tumor versus normal tissue (log2 FC = +0.944, t-test p < 0.001).
This table shows molecular features associated with TTC9C in patient tissues and cancer cell lines. In patient samples, TTC9C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC9C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
